Ketolorac is developed by The Cleveland Clinic.

What development phase is Ketolorac in?

Ketolorac is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Ketolorac

The Cleveland Clinic · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Ketolorac
Also known as	Toradol
Sponsor	The Cleveland Clinic
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Low Dose Versus Normal Dose Ketorolac for Postoperative Pain After Prostatectomy and Hysterectomy (NA)
"The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors" (PHASE2)
Acute Pain and Inflammation After Surgery (PHASE4)
Ketolorac Versus Saline at Laparoscopic Incision Sites (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ketolorac CI brief — competitive landscape report
Ketolorac updates RSS · CI watch RSS
The Cleveland Clinic portfolio CI